These results in combination with the inherent properties of 177Lu-PSMA-617 have led to its current exploration as a promising treatment modality beyond progressive metastatic castration-resistant prostate cancer, and into the earlier phases of prostate cancer. This evidence concerns the gene FOLH1 and Familial prostate cancer.